ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it is exhibiting at the 8th European Masters in Aesthetics & Anti-Aging (EMAA) in Paris, October 12-14, 2012, and will highlight CoolCurve+, the newest addition to the applicator platform for the CoolSculpting® System. Designed for enhanced fit and tissue draw, the anatomically curved shape of the CoolCurve+ applicator allows physicians to treat a multitude of body shapes. CoolSculpting is a non-surgical, clinically proven procedure that selectively reduces fat bulges in problem areas using a patented cooling technology.
|ZELTIQ Aesthetics Booth, Stand A23|
|Friday, October 12, 2012, 2:00 – 7:00 p.m.|
Saturday, October 13, 2012, 8:00 a.m. – 6:30 p.m.
Sunday, October 14, 2012, 8:30 a.m. – 1:00 p.m.
|European Master in Aesthetics & Anti-Aging Medicine (EMAA)|
|Palais des Congres de Paris|
|2, place de la Porte Maillot|
About ZELTIQ Aesthetics, Inc.
ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ) is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.